EyePoint reduces staff in response to COVID-19

EyePoint Pharmaceuticals has reorganized its operations and will downsize its workforce in the wake of the COVID-19 outbreak, according to a press release.
Reductions to the Dexycu (dexamethasone intraocular suspension 9%) sales force and supporting commercial operations make up the majority of the cuts, as cataract surgery is considered a nonessential procedure during the pandemic.
Commercial operations for Yutiq (fluocinolone acetonide intravitreal implant 0.18 mg) will continue, as noninfectious uveitis treatments are deemed essential, the release said.
The company expects to save

Full Story →